Evidence map›Paper›PMID 23419168›Full record

ArticleDiagnostic pathology2013

CD44/CD24 immunophenotypes on clinicopathologic features of salivary glands malignant neoplasms.

Danilo Figueiredo Soave, João Paulo Oliveira da Costa, Giorgia Gobbi da Silveira, Renata Carolina Fraga Ianez, Lucinei Roberto de Oliveira, Silvia Vanessa Lourenço, Alfredo Ribeiro-Silva

Open access · goldAbstract read
In one paragraph

Article in Diagnostic pathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Cancer stem cell markers in adenocarcinoma of the salivary glands - reliable prognostic markers?European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2021
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Danilo Figueiredo SoaveDepartment of Pathology, Ribeirão Preto Medical School, University of São Paulo, Avenida Bandeirantes; Number: 3900, Ribeirão Preto, São Paulo 14049-900, Brazil.
João Paulo Oliveira da Costa
Giorgia Gobbi da Silveira
Renata Carolina Fraga Ianez
Lucinei Roberto de Oliveira
Silvia Vanessa Lourenço
Alfredo Ribeiro-Silva
Hospital Bandeirantes · BRUniversidade de São Paulo · BRAC Camargo Hospital · BRClinics Hospital of Ribeirão Preto · BRUniversidade de Ribeirão Preto · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSalivary glands malignant neoplasms (SGMNs) account for 3-6% of head and neck cancers and 0.3% of all cancers. Tumor cells that express CD44 and CD24 exhibit a stem-cell-like behavior. CD44 is the binding site for hyaluronic acid, and CD24 is a receptor that interacts with P-selectin to induce metastasis and tumor progression. The present study aims to evaluate the expression of CD44 and CD24 on SGMNs and correlated these data with several clinicopathologic features.

methodsImmunohistochemical stains for CD44 and CD24 were performed on tissue microarrays containing SGMN samples from 69 patients. The CD44, CD24 and CD44/CD24 expression phenotypes were correlated to patient clinicopathologic features and outcome.

resultsCD44 expression was associated with the primary site of neoplasm (p = 0.046). CD24 was associated with clinical stage III/IV (p = 0.008), T stage (p = 0,27) and lymph node (p = 0,001). The CD44/CD24 profiles were associated with the primary site of injury (p = 0.005), lymph node (p = 0.011) and T stage (p = 0.023). Univariate analysis showed a significant relationship between clinical staging and disease- free survival (p = 0.009), and the overall survival presents relation with male gender (p = 0.011) and metastasis (p = 0.027).

conclusionIn summary, our investigation confirms that the clinical stage, in accordance with the literature, is the main prognostic factor for SGMN. Additionally, we have presented some evidence that the analysis of isolated CD44 and CD24 immunoexpression or the two combined markers could give prognostic information associated to clinicopathologic features in SGMN. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1284611098470676.

Indexed as

ImmunophenotypingAdolescentAdultAgedAged, 80 and overBiomarkers, TumorCarcinomaCD24 AntigenChi-Square DistributionDisease-Free SurvivalFemaleHumansHyaluronan ReceptorsImmunohistochemistryKaplan-Meier EstimateLymphatic MetastasisBiomarkers, TumorCD24 AntigenCD24 protein, humanCD44 protein, humanHyaluronan Receptors

Identifiers

PMID23419168
PMCPMC3605183
OpenAlexW2101827604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.